ABT pre-earnings setup: report due 2026-07-16ABT 财报前观察：预计 2026-07-16 发布
Setup
Abbott Laboratories (ABT) will release its Q2 2026 earnings report on July 16, 2026, with a current market capitalization of $166.2 billion. Wall Street consensus estimates call for $1.28 in EPS and $12.5184 billion in total revenue for the quarter, making this a key healthcare sector earnings event in the near term.
Pre-Report Context
This report follows ABT’s better-than-expected Q1 2026 results: in the April 16, 2026 earnings release, the company posted adjusted EPS of $1.15, beating the consensus estimate of $1.14, and total revenue of $11.164 billion, exceeding the consensus forecast of $10.996 billion. Institutional holdings data as of December 31, 2025 shows 3,310 institutional holders, representing 81.7% of the company’s float, with a net increase of 68 holders from the prior period, including 321 new positions and 1,468 increased positions, signaling consistent institutional confidence in the stock.
Cross-Check Signals
Two concrete public signals offer additional context: first, on June 18, 2026, director Stratton John G purchased 2,000 shares of ABT at $86.82 per share for a total of $173,640, marking the only open-market insider buy in the prior 30 days. Second, SEC Form 4 filings dated July 1, 2026 show equity awards to six board members and executive officers, including Executive Vice President Louis H. Morrone who received 269 shares valued at $24,939 at the prevailing market price. Analyst ratings have held steady since May 2026, with 4 strong buy, 17 buy, and 7 hold ratings as of June 1, with a minor shift in breakdown but an overall bullish tilt.
Follow-Up Markers
Investors should prioritize verifying reported EPS against the $1.28 consensus, actual revenue against the $12.5184 billion target, gross profit margins, operating cash flow, full-year 2026 guidance, and segment-specific operating results for ABT’s four core divisions. This signal does not predict stock price movement or future financial performance, and does not constitute investment advice.
前置设置
雅培实验室（ABT）将于2026年7月16日发布2026年第二季度财报，当前市值达1662亿美元。市场一致预期该季度每股收益（EPS）为1.28美元，总营收为125.184亿美元，这一报告是近期医疗健康板块的核心业绩事件。
财报前的关注背景
本次财报紧随雅培2026年第一季度的超预期表现：2026年4月16日发布的第一季度财报中，实际EPS为1.15美元，高于市场预期的1.14美元，实际营收111.64亿美元，高于预期的109.996亿美元。同时，截至2025年12月31日的机构持仓数据显示，共有3310家机构持有雅培流通股，占比达81.7%，较上一季度增加68家机构，其中321家新建仓、1468家加仓，显示机构对该股的持续配置信心。
交叉验证信号
近期有两项具体公开信号可作为参考：一是2026年6月18日，雅培董事Stratton John G以86.82美元/股的价格在公开市场买入2000股公司股票，总成交额达173640美元，这是近30天内唯一一笔非股权激励的内部人员买入交易；二是2026年7月1日提交的SEC Form 4文件显示，包括执行副总裁Louis H. Morrone在内的多名董事和高管获得股权激励，其中Morrone获得269股，按当日市价92.71美元计算价值约24939美元。分析师评级方面，截至2026年6月1日，覆盖该股的分析师中4家给予强力买入、17家给予买入、7家给予持有，评级结构较上月微调但整体维持看多倾向。
后续关注要点
投资者需重点关注本次财报披露的实际EPS与1.28美元市场预期的偏差、实际营收与125.184亿美元预期的偏差，同时需核对毛利率、自由现金流、2026年全年业绩指引，以及雅培四大核心业务板块的细分运营表现。本信号不预判股价走势，也不构成任何投资建议。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。